GlaxoSmithKline

GSK PLC is assigned a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 4% discount to our quantitative fair value estimate of $51.70 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.

The company's profitability increases our estimated fair value. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. For example, the firm's earnings yield of 9.2% ranks in the top 30% compared with peers globally. This suggests that it is generating substantial earnings relative to its share price, which contributes to our view that shares are cheap.

Alternatively, the company's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 23.3%, for example, lies in the bottom 20% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

The company earns a quantitative moat rating of wide, suggesting a strong ability to maintain superior profitability thanks to competitive advantages that could persist up to two decades. This is supported by the company's strong financial health score, which indicates a low likelihood that the company will tumble into financial distress.